Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05660291
Other study ID # 22-010547
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date February 24, 2023
Est. completion date December 2024

Study information

Verified date April 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to understand the difference between early and late time-restricted eating on weight and body mass index (BMI), and evaluate the barriers encountered and the effect on quality of life.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Ability to read and understand English - BMI = to 25. Exclusion Criteria: - Regularly skip meals. - Are unwilling or unable to limit eating to an 8-hour window. - Have a current Melanoma or cancer diagnosis. - Currently breastfeeding. - Pregnant, or planned to be pregnant within 3 months. - Are taking insulin or sulfonylurea drugs. - Are taking weight loss medications or had weight loss surgery within the last year. - Have a history of eating disorders.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Early time-restricted eating
Subjects can eat whatever they want between the hours of 8:00 AM and 4:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 4:00 PM to 8:00 AM).
Late time-restricted eating
Subjects can eat whatever they want between the hours of 12:00 PM and 8:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 8:00 PM to noon).

Locations

Country Name City State
United States Mayo Clinic Minnesota Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in weight Reported in kilograms (kg) Baseline, 12 weeks
Secondary Change in Hemoglobin A1c Hemoglobin is a protein within red blood cells. As glucose enters the bloodstream, it binds to hemoglobin, or glycates. The more glucose that enters the bloodstream, the higher the amount of glycated hemoglobin. An A1C level below 5.7 percent is considered normal. Reported as percentage of glycated hemoglobin Baseline, 12 weeks
Secondary Change in fasting glucose Glucose (sugar) measured in the blood and reported in milligrams per deciliter (mg/dL). Baseline, 12 weeks
Secondary Change in total cholesterol Blood sample taken to measure the sum of blood's cholesterol content and reported in milligrams/deciliter (mg/dL) Baseline, 12 weeks
Secondary Change in Low-density lipoprotein (LDL) cholesterol LDL (bad) cholesterol measured in the blood and reported in milligrams/deciliter (mg/dL) Baseline, 12 weeks
Secondary Change in High-density lipoprotein (HDL) cholesterol HDL (good) cholesterol measured in the blood and reported in milligrams/deciliter (mg/dL) Baseline, 12 weeks
Secondary Change in Triglycerides Triglycerides levels measured in the blood and reported in milligrams/deciliter (mg/dL) Baseline, 12 weeks
Secondary Subjects to complete study Total number of subjects to complete study per protocol Baseline, 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03759743 - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject N/A
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Not yet recruiting NCT05751993 - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions N/A
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Completed NCT02899390 - Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4